Source 1primary paper2023ACS Nano
Toolkit/camouflage nanoparticle-based vector
camouflage nanoparticle-based vector
Also known as: biomimetic vectors, camouflage nanoparticle-based optogenetic system
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Camouflage nanoparticle-based vectors are biomimetic delivery systems developed for in situ bioluminescence-driven optogenetic therapy of retinoblastoma. In the cited 2023 ACS Nano study, this system enabled optogenetic treatment and showed greater tumor inhibition than external blue light irradiation.
Usefulness & Problems
Why this is useful
This delivery harness is useful for implementing optogenetic therapy in retinoblastoma using in situ bioluminescence rather than relying solely on external blue light exposure. The reported comparative efficacy suggests it can improve therapeutic output in ocular tumors.
Source:
Herein, we present the demonstration of camouflage nanoparticle-based vectors for in situ bioluminescence-driven optogenetic therapy of retinoblastoma. To conduct proof-of-concept research, this study employs a mouse model of retinoblastoma.
Problem solved
The system addresses the challenge of delivering and activating optogenetic therapy within retinoblastoma in situ. It specifically aims to overcome the lower therapeutic efficacy observed with external blue light irradiation in the cited comparison.
Source:
Herein, we present the demonstration of camouflage nanoparticle-based vectors for in situ bioluminescence-driven optogenetic therapy of retinoblastoma. To conduct proof-of-concept research, this study employs a mouse model of retinoblastoma.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Techniques
Structural CharacterizationTarget processes
No target processes tagged yet.
Input: Light
Implementation Constraints
The system is described as a camouflage nanoparticle-based, biomimetic vector used for in situ bioluminescence-driven optogenetic therapy in retinoblastoma. The supplied evidence does not report construct architecture, optical components, formulation details, dosing, or delivery route.
The provided evidence is limited to a single cited study in retinoblastoma and does not specify nanoparticle composition, payload design, or quantitative performance metrics. No independent replication, broader disease validation, or mechanistic detail beyond bioluminescence-driven activation and nanoparticle-mediated delivery is provided here.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Observations
successMouseapplication demomouse model of retinoblastoma
Inferred from claim c2 during normalization. Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size. Derived from claim c2. Quoted text: In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
Source:
ocular tumor size(significant_reduction)
successMouseapplication demomouse model of retinoblastomaretina
Inferred from claim c3 during normalization. Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization. Derived from claim c3. Quoted text: Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Source:
successMouseapplication demomouse model of retinoblastoma
Inferred from claim c2 during normalization. Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size. Derived from claim c2. Quoted text: In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
Source:
ocular tumor size(significant_reduction)
successMouseapplication demomouse model of retinoblastomaretina
Inferred from claim c3 during normalization. Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization. Derived from claim c3. Quoted text: Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Source:
successMouseapplication demomouse model of retinoblastoma
Inferred from claim c2 during normalization. Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size. Derived from claim c2. Quoted text: In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
Source:
ocular tumor size(significant_reduction)
successMouseapplication demomouse model of retinoblastomaretina
Inferred from claim c3 during normalization. Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization. Derived from claim c3. Quoted text: Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Source:
successMouseapplication demomouse model of retinoblastoma
Inferred from claim c2 during normalization. Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size. Derived from claim c2. Quoted text: In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
Source:
ocular tumor size(significant_reduction)
successMouseapplication demomouse model of retinoblastomaretina
Inferred from claim c3 during normalization. Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization. Derived from claim c3. Quoted text: Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Source:
successMouseapplication demomouse model of retinoblastoma
Inferred from claim c2 during normalization. Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size. Derived from claim c2. Quoted text: In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
Source:
ocular tumor size(significant_reduction)
successMouseapplication demomouse model of retinoblastomaretina
Inferred from claim c3 during normalization. Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization. Derived from claim c3. Quoted text: Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Source:
successMouseapplication demomouse model of retinoblastoma
Inferred from claim c2 during normalization. Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size. Derived from claim c2. Quoted text: In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
Source:
ocular tumor size(significant_reduction)
successMouseapplication demomouse model of retinoblastomaretina
Inferred from claim c3 during normalization. Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization. Derived from claim c3. Quoted text: Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Source:
successMouseapplication demomouse model of retinoblastoma
Inferred from claim c2 during normalization. Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size. Derived from claim c2. Quoted text: In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
Source:
ocular tumor size(significant_reduction)
successMouseapplication demomouse model of retinoblastomaretina
Inferred from claim c3 during normalization. Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization. Derived from claim c3. Quoted text: Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Source:
Supporting Sources
Ranked Claims
Camouflage nanoparticle-based vectors were demonstrated for in situ bioluminescence-driven optogenetic therapy of retinoblastoma.
Herein, we present the demonstration of camouflage nanoparticle-based vectors for in situ bioluminescence-driven optogenetic therapy of retinoblastoma. To conduct proof-of-concept research, this study employs a mouse model of retinoblastoma.
Camouflage nanoparticle-based vectors were demonstrated for in situ bioluminescence-driven optogenetic therapy of retinoblastoma.
Herein, we present the demonstration of camouflage nanoparticle-based vectors for in situ bioluminescence-driven optogenetic therapy of retinoblastoma. To conduct proof-of-concept research, this study employs a mouse model of retinoblastoma.
Camouflage nanoparticle-based vectors were demonstrated for in situ bioluminescence-driven optogenetic therapy of retinoblastoma.
Herein, we present the demonstration of camouflage nanoparticle-based vectors for in situ bioluminescence-driven optogenetic therapy of retinoblastoma. To conduct proof-of-concept research, this study employs a mouse model of retinoblastoma.
Camouflage nanoparticle-based vectors were demonstrated for in situ bioluminescence-driven optogenetic therapy of retinoblastoma.
Herein, we present the demonstration of camouflage nanoparticle-based vectors for in situ bioluminescence-driven optogenetic therapy of retinoblastoma. To conduct proof-of-concept research, this study employs a mouse model of retinoblastoma.
Camouflage nanoparticle-based vectors were demonstrated for in situ bioluminescence-driven optogenetic therapy of retinoblastoma.
Herein, we present the demonstration of camouflage nanoparticle-based vectors for in situ bioluminescence-driven optogenetic therapy of retinoblastoma. To conduct proof-of-concept research, this study employs a mouse model of retinoblastoma.
Camouflage nanoparticle-based vectors were demonstrated for in situ bioluminescence-driven optogenetic therapy of retinoblastoma.
Herein, we present the demonstration of camouflage nanoparticle-based vectors for in situ bioluminescence-driven optogenetic therapy of retinoblastoma. To conduct proof-of-concept research, this study employs a mouse model of retinoblastoma.
Camouflage nanoparticle-based vectors were demonstrated for in situ bioluminescence-driven optogenetic therapy of retinoblastoma.
Herein, we present the demonstration of camouflage nanoparticle-based vectors for in situ bioluminescence-driven optogenetic therapy of retinoblastoma. To conduct proof-of-concept research, this study employs a mouse model of retinoblastoma.
Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size.
In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
ocular tumor size significant reduction
Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size.
In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
ocular tumor size significant reduction
Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size.
In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
ocular tumor size significant reduction
Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size.
In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
ocular tumor size significant reduction
Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size.
In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
ocular tumor size significant reduction
Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size.
In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
ocular tumor size significant reduction
Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size.
In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
ocular tumor size significant reduction
Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization.
Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization.
Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization.
Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization.
Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization.
Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization.
Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization.
Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Approval Evidence
1 source3 linked approval claimsfirst-pass slug camouflage-nanoparticle-based-vector
camouflage nanoparticle-based vectors for in situ bioluminescence-driven optogenetic therapy of retinoblastoma
Source:
application demonstrationsupports
Camouflage nanoparticle-based vectors were demonstrated for in situ bioluminescence-driven optogenetic therapy of retinoblastoma.
Herein, we present the demonstration of camouflage nanoparticle-based vectors for in situ bioluminescence-driven optogenetic therapy of retinoblastoma. To conduct proof-of-concept research, this study employs a mouse model of retinoblastoma.
Source:
comparative efficacysupports
Compared with external blue light irradiation, the developed system inhibited tumor growth with greater therapeutic efficacy and significantly reduced ocular tumor size.
In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
Source:
safety comparisonsupports
Unlike external blue light irradiation, the camouflage nanoparticle-based optogenetic system maintained retinal structural integrity and avoided corneal neovascularization.
Furthermore, unlike external blue light irradiation, which causes retinal damage and corneal neovascularization, the camouflage nanoparticle-based optogenetic system maintains retinal structural integrity while avoiding corneal neovascularization.
Source:
Comparisons
Source-backed strengths
The available evidence shows application in retinoblastoma and demonstrates in situ bioluminescence-driven optogenetic therapy. In the reported study, the developed system inhibited tumor growth more effectively than external blue light irradiation and significantly reduced ocular tumor size.
Source:
In comparison to external blue light irradiation, the developed system enables an in situ bioluminescence-activated apoptotic pathway to inhibit tumor growth with greater therapeutic efficacy, resulting in a significant reduction in ocular tumor size.
Ranked Citations
- 1.